Searching and assessing stem cell medicines
Challenge
A listed North American firm needed support with the identification of early-stage in-licensing or acquisition opportunities in the highly competitive field of regenerative medicine. Alacrita was engaged to perform the search.
Solution
We conducted a scouting exercise for late-stage academic or seed-/early-stage commercial programs in the field of regenerative stem cell therapies. By leveraging our extensive network in academia and early-stage private companies, we were able to introduce our client to a number of opportunities that were not previously known to them nor were they yet listed in syndicated licensing databases. The client then conducted its own detailed assessment of these opportunities.
Related Case Studies
Explore similar engagements and see how we've helped other clients achieve their goals.
Scouting for assets discontinued from development due to neutralizing antibodies (Nabs)
Asset scouting for novel injectable formulations for large pharma
In-Licensing Support and Asset Scouting in CNS
Scouting for autoimmune / auto-inflammatory assets
Interested in Learning More?
Contact us to discuss how we can support your project with similar expertise.